Background: Reduced eGFR is associated with increased risk of cardiovascular disease and mortality.
Methods: Of 370 men with hypogonadism and T2DM, 190 received testosterone undecanoate 1000 mg/12 weeks (T-group) , 180 opted against treatment (CTRL) . Means and standard deviations of absolute measures over 13 years are reported. eGFR was calculated using the MDRD and the CKD-EPI formula.
Results: Mean baseline age: 62.0±5.2, mean (median) follow-up: 9.3±3.1 (10) years. Creatinine (mg/dL) decreased from 0.95±0.15 to 0.81±0.in the T-group and increased from 1.00±0.14 to 1.27±0.22 in CTRL (p<0.00for both) .
Systolic blood pressure (mmHg) decreased in the T-group from 163.0±13.3 to 129.8±6.5 and increased in CTRL from 145.5±14.5 to 162.9±13.1 (p<0.00for both) .
Diastolic blood pressure decreased in the T-group from 97.3±10.7 to 74.8±3.1 and increased in CTRL from 84.7±10.2 to 96.8±7.5 (p<0.00for both) .
T-group: eGFR (MDRD) (mL/min/1.73 m²) increased from 82.5±12.8 to 94.4±9.1. CTRL: eGFR decreased from 77.2±12.1 to 56.9±10.6) (p<0.00for both) .
T-group: eGFR (CKD-EPI) (mL/min/1.73 m²) increased from 84.0±15.4 to 87.5±4.7. CTRL: eGFR decreased from 77.0±13.9 to 49.8±12.3) (p<0.00for both) .
21 deaths (11.1%) and no cardiovascular events occurred in the T-group. In CTRL, 62 deaths (34.4%) , 62 myocardial infarctions (34.4%) and 51 strokes (28.3%) were recorded (p<0.00for all) . Nephropathy occurred in 1 man (0.01%) in the T-group and in 7 (0.4%) in CTRL (p=0.05) .
Conclusions: Long-term testosterone therapy in men with hypogonadism and T2DM prevents age-related deterioration in GFR.
K.S.Haider: Other Relationship; Bayer AG. A.Haider: Other Relationship; Bayer AG. F.Saad: Consultant; Bayer AG, Stock/Shareholder; AbbVie Inc., Bayer AG, GlaxoSmithKline plc.